Cost-effectiveness analysis of a large jail-based methadone maintenance treatment continuation program in New Mexico

被引:7
|
作者
Horn, Brady P. [1 ,2 ]
Li, Xiaoxue [1 ]
McCrady, Barbara [2 ,3 ]
Guerin, Paul [4 ]
French, Michael T. [5 ]
机构
[1] Univ New Mexico, Dept Econ, MSC 05 3060,1 Univ New Mexico, Albuquerque, NM 87131 USA
[2] Univ New Mexico, Ctr Alcoholism Subst Abuse & Addict CASAA, 2650 Yale SE MSC11-6280, Albuquerque, NM 87106 USA
[3] Univ New Mexico, Dept Psychol, MSC 05 3060,1 Univ New Mexico, Albuquerque, NM 87131 USA
[4] Univ New Mexico, Inst Social Res, 1915 Las Lomas, Albuquerque, NM 87131 USA
[5] Univ Miami, Miami Herbert Business Sch, Dept Hlth Management & Policy, Coral Gables, FL 33124 USA
关键词
Opioid use disorder; Methadone maintenance; Cost-effectiveness analysis; Jail; Recidivism; SUBSTANCE-ABUSE TREATMENT; ECONOMIC-EVALUATION; DRUG-ABUSE; PRISON; ADDICTION; COMMUNITY; COURT;
D O I
10.1016/j.jsat.2020.108042
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The U.S. has the second-highest incarceration rate in the world and spends more than $80 billion annually to house inmates. The clinical research literature suggests that methadone maintenance treatment (MMT) is an effective method to treat opioid use disorders (OUD) and that jails are a potentially valuable environment to implement MMT. Currently, jail-based MMT is rarely implemented in practice, due in part to resource limitations and other economic considerations. The primary goal of this study was to perform a cost-effectiveness analysis (CEA) of jail-based MMT using data from a unique MMT continuation program located in a large urban jail in New Mexico. Recidivism data were collected for a three-year period both before and after incarceration, and quasi-control groups were constructed from both substance-using and general populations within the jail. Base models show that inmates enrolled in jail-based MMT exhibited significantly fewer days of incarceration due to recidivism (29.33) than a group of inmates with OUDs who did not receive MMT. Economic estimates indicate that it cost significantly less ($23.49) to reduce an incarcerated day using jail-based MMT than incarceration per se ($116.49). To mitigate potential sample selection bias, we used both propensity-score-matching and difference-in-differences estimators, which provided comparable estimates when using the OUD non-MMT comparison group. Difference-in-differences models find that, on average, MMT reduced recidivism by 24.80 days and it cost $27.78 to reduce an incarcerated day using jail-based MMT. Assuming a willingness to pay threshold of the break-even cost of reducing one incarcerated day, we estimate a 93.3% probability that this MMT program is cost-effective. Results were not as strong or consistent when using other comparison groups (e.g., alcohol-detoxified and general-population inmates). Overall, results suggest that it costs substantially less to provide jail-based MMT than incarceration alone. Jail administrators and policymakers should consider incorporating MMT in other jail systems and settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis
    Fariman, Soroush Ahmadi
    Rafsanjani, Zahra Jahangard
    Hasanzad, Mandana
    Niksalehi, Kimia
    Nikfar, Shekoufeh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 71 - 80
  • [42] Cost-Effectiveness Analysis of Risk Factor-Based Lung Cancer Screening Program by Low-Dose Computer Tomography in Current Smokers in China
    Zhang, Tiantian
    Chen, Xudong
    Li, Caichen
    Wen, Xiaoqin
    Lin, Tengfei
    Huang, Jiaxing
    He, Jianxing
    Zhong, Nanshan
    Jiang, Jie
    Liang, Wenhua
    CANCERS, 2023, 15 (18)
  • [43] Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population
    Tan, Chongqing
    Li, Sini
    Yi, Lidan
    Zeng, Xiaohui
    Peng, Liubao
    Qin, Shuxia
    Wang, Liting
    Wan, Xiaomin
    ADVANCES IN THERAPY, 2021, 38 (05) : 2571 - 2585
  • [44] Cost-effectiveness and budget impact analysis of vinflunine used in the treatment of patients with urothelial transitional cell carcinoma resistant to platinum-based regimens
    Kulikov, A. Yu.
    Rybchenko, Yu. V.
    ONKOUROLOGIYA, 2015, 11 (02): : 40 - 45
  • [45] Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach
    Kurte, Melina Sophie
    Siefen, Ann-Cathrine
    Jakobs, Florian
    von Tresckow, Bastian
    Reinhardt, Hans Christian
    Kron, Florian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (06) : 895 - 908
  • [46] Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa (r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry
    Buehler, Klaus
    Roeder, Claudia
    Schwarze, Juan-Enrique
    Lispi, Monica
    Allignol, Arthur
    Falla, Edel
    Lukyanov, Vasily
    DHooghe, Thomas
    Fischer, Robert
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2022, 85 : 188 - 202
  • [47] Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis
    Shih, Sophy T. F.
    Cheng, Qinglu
    Carson, Joanne
    Valerio, Heather
    Sheehan, Yumi
    Gray, Richard T.
    Cunningham, Evan B.
    Kwon, Jisoo A.
    Lloyd, Andrew R.
    Dore, Gregory J.
    Wiseman, Virginia
    Grebely, Jason
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 36
  • [48] Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
    Qiuling Zhao
    Ruixiang Xie
    Wanfu Zhong
    Wenbin Liu
    Ting Chen
    Xiuliang Qiu
    Lin Yang
    Cost Effectiveness and Resource Allocation, 21
  • [49] Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
    Zhao, Qiuling
    Xie, Ruixiang
    Zhong, Wanfu
    Liu, Wenbin
    Chen, Ting
    Qiu, Xiuliang
    Yang, Lin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [50] Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
    Garcia-Sancho, Alejandro Martin
    Presa, Maria
    Pardo, Carlos
    Martin-Escudero, Victoria
    Oyaguez, Itziar
    Ortiz-Maldonado, Valentin
    CANCERS, 2024, 16 (13)